Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Smith

Clinical Cardiac Electrophysiology Wilmington, NC Medical Doctor

NPI 1144338161 CMS profile 97516

1500 Physicians Dr, Wilmington, NC 28401

Open in the dashboard

General payments

$51,710

372 records reported · program years 2019–2025

Research payments

$59,486

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,650,062 paid to institutions, not to them · program years 2023–2025

Through program year 2025, William Smith of Wilmington, NC is reported in the CMS Open Payments database as having received $51,710 across 372 general payments and $59,486 in research payments paid to them. Separately, studies naming them as principal investigator received $1,650,062 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,536 82
2024 General $4,537 95
2024 Research $59,486 3
2023 General $5,124 89
2022 General $1,311 28
2021 General $325 12
2020 General $3,948 18
2019 General $30,928 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Smith
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to William Smith were reported at $5,536. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year William Smith Clinical Cardiac Electrophysiology median Middle half National median
2019 $30,928 $2,361 $585–$8,260 $163
2020 $3,948 $993 $247–$4,351 $114
2021 $325 $1,185 $326–$4,739 $132
2022 $1,311 $2,073 $554–$6,789 $149
2023 $5,124 $2,568 $759–$8,159 $160
2024 $4,537 $2,557 $703–$7,403 $164
2025 $5,536 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $22,992 18 payments
  2. E.R. Squibb & Sons, L.L.C. $7,243 4 payments
  3. Medtronic, Inc. $4,947 65 payments
  4. Boston Scientific Corporation $4,475 118 payments
  5. Medtronic Vascular, Inc. $4,273 33 payments
  6. Abbott Laboratories $3,606 61 payments
  7. Atricure, Inc. $1,401 26 payments
  8. Biosense Webster, Inc. $634 12 payments
  9. Eli Lilly and Company $605 1 payment
  10. Philips Electronics North America Corporation $298 4 payments
  11. Other $1,236 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,775 10 payments
  2. Food and Beverage $13,668 331 payments
  3. Travel and Lodging $6,624 29 payments
  4. Consulting Fee $625 1 payment
  5. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $22,973 17 payments
  2. ELIQUIS Cardiovascular $7,243 4 payments
  3. Arctic Front $3,474 9 payments
  4. AVEIR $1,612 9 payments
  5. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $1,401 26 payments
  6. WATCHMAN FLX $1,252 74 payments
  7. INGEVITY+ $650 2 payments
  8. WATCHMAN Access System $479 17 payments
  9. AZURE XT DR MRI SURESCAN $466 5 payments
  10. COBALT DR MRI SURESCAN $423 5 payments
  11. Other $7,232 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $59,486 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

2,913

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$670,954

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

35.8%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 456 $474,735
Xarelto Rivaroxaban Brand 76 $80,696
Entresto Sacubitril/Valsartan Brand 18 $32,640
Repatha Sureclick Evolocumab Brand 22 $25,583
Dofetilide Generic 52 $13,540
Metoprolol Succinate Generic 508 $8,283
Flecainide Acetate Generic 125 $6,463
Propafenone Hcl Er Propafenone Hcl Brand 17 $6,271
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 148 $3,667
Sotalol Sotalol Hcl Brand 145 $2,580

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$211,784

Medicare's payments for the services billed

Medicare patients

1,513

Average age 78

Services billed

4,070

618 women, 895 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 71%
Ischemic heart disease 53%
Arthritis 51%
Heart failure 43%
Diabetes 35%
Chronic kidney disease 34%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $37
$37 22 —
VERQUVO
  • Merck Sharp & Dohme Corporation $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

375 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record